NEW YORK,
Nov. 5, 2018 /PRNewswire/ --
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
announced today that it has been selected to present at the
BIO-Europe® 24th Annual International
Partnering Conference. The presentation is in addition to the
Company's planned partnering activities at the conference.
Sandesh Seth, Actinium's Chairman
and CEO will provide an overview of the Company's Antibody
Radiation Conjugate (ARC) programs including its Iomab-B program
and preliminary data from its pivotal Phase 3 SIERRA trial that has
been accepted for oral presentation at ASH, its Iomab-ACT program
for targeted lymphodepletion prior to CAR-T, its best in class CD33
program and its Antibody Warhead Enabling (AWE) technology
platform.
Presentation Details
Venue: Bella
Center Copenhagen
Date: Tuesday, November 6, 2018
Time:
9:00 AM CET
Room: B2
on level 0
Category: Oncology
About BIO-Europe
The 24th annual BIO-Europe is Europe's largest partnering conference serving
the global biotechnology industry. Delegates from all parts of the
biotechnology value chain come to BIO-Europe to quickly identify,
engage and enter strategic relationships that drive their
businesses successfully forward. Investment and collaboration
opportunities developed in prior BIO-Europe conferences have
produced many highly successful business partnerships. BIO-Europe
is organized by EBD Group, the leading partnering firm for the
global biotechnology industry, in alliance with the Biotechnology
Industry Organization (BIO)
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving
patient access and outcomes to cellular therapies such as bone
marrow transplant (BMT) and CAR-T with its proprietary,
chemotherapy free or sparing, targeted conditioning technology.
Actinium is the only company with a multi-disease, multi-target,
drug development pipeline focused on targeted conditioning. Its
targeted conditioning technology is enabled by ARC's or Antibody
Radiation Conjugates that combine the targeting ability of
monoclonal antibodies with the cell killing ability of
radioisotopes. Actinium's pipeline of clinical-stage targeted
conditioning ARCs target the antigens CD45 and CD33 for patients
with a broad range of hematologic malignancies including acute
myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple
myeloma (MM), acute lymphoblastic leukemia (ALL), Hodgkin's
lymphoma and Non-Hodgkin's lymphoma. Actinium's Iomab-ACT program
is designed to be a universal lymphodepletion technology intended
to eliminate the need for chemotherapy-based conditioning prior to
CAR-T or other adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131-apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal,
chemotherapy-free solution for targeted lymphodepletion prior to
CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is
expected to improve CAR-T cell expansion, reduce CAR-T related
toxicities and expand patient access to CAR-T treatment and
potentially other adoptive cell therapies. Due to its lower payload
dose, lymphodepletion with the Iomab-ACT program can be
accomplished through a single outpatient infusion. Actinium intends
to advance its Iomab-ACT program with CAR-T focused collaborators
from academia and industry.
Actinium's pipeline also includes a potentially
best-in-class CD33 program with its ARC comprised of the anti-CD33
antibody lintuzumab labeled with the alpha-particle emitter
actinium-225. Its CD33 program is currently being studied in
multiple clinical trials for targeting conditioning and as a
therapeutic in multiple diseases and indications including AML, MDS
and MM. Actinium applies its CD33 program at high doses to target
CD33+ cells of the myeloid lineage in combination with reduced
intensity conditioning (RIC), which together are intended to result
in myeloablative outcomes with a more benign and well tolerated
profile than high intensity chemotherapy myeloablation. Actinium is
focused on applying its CD33 program at low doses in combination
with other therapeutic modalities including chemotherapy, targeted
agents and immunotherapies.
Actinium is also developing its proprietary AWE or
Antibody Warhead Enabling technology platform which utilizes
radioisotopes including iodine-131 and the highly differentiated
actinium-225 coupled with antibodies to target a variety of
antigens that are expressed in hematological and solid tumor
cancers. The AWE technology enables Actinium's internal pipeline
and with the radioisotope Actinium-225 is being utilized in a
collaborative research partnership with Astellas Pharma, Inc.
Actinium's clinical programs and AWE technology platform are
covered by a portfolio of 75 patents covering composition of
matter, formulations, methods of use and also methods of
manufacturing the radioisotope Actinium-225 in a
cyclotron.
More information is available at
www.actiniumpharma.com and our Twitter feed
@ActiniumPharma,
www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium
Pharmaceuticals, Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Rx
Communications Group
Paula
Schwartz
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-at-bio-europe-24th-annual-international-partnering-conference-300743727.html
SOURCE Actinium Pharmaceuticals, Inc.